scholarly article | Q13442814 |
P50 | author | Maria G Tektonidou | Q57034988 |
Haralampos Moutsopoulos | Q87896552 | ||
Demosthenes B. Panagiotakos | Q87944029 | ||
P2093 | author name string | Katerina Laskari | |
P2860 | cites work | Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome | Q33333387 |
Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance | Q33392960 | ||
Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 | ||
Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis | Q48394757 | ||
P433 | issue | 1 | |
P921 | main subject | systemic lupus erythematosus | Q1485 |
thrombosis | Q261327 | ||
P304 | page(s) | 29-36 | |
P577 | publication date | 2009-01-01 | |
P1433 | published in | Arthritis and Rheumatism | Q23929027 |
P1476 | title | Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies | |
P478 | volume | 61 |
Q53245134 | A 26-year-old white man with a systemic lupus erythematosus flare and acute multiorgan ischemia: Vasculitis or thrombosis? |
Q42830956 | Acquired hemophilia A and von Willebrand syndrome in a patient with late-onset systemic lupus erythematosus |
Q34069117 | Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. |
Q90264610 | Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study |
Q64956251 | Antimalarials - are they effective and safe in rheumatic diseases? |
Q35756040 | Antiphospholipid Syndrome during pregnancy: the state of the art |
Q55891386 | Antiphospholipid syndrome |
Q64046338 | Antiphospholipid syndrome |
Q37721617 | Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? |
Q38679842 | Antiphospholipid syndrome: an update for clinicians and scientists |
Q36477921 | At the Bench: Neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases |
Q35008643 | Autoimmunity and recurrent pregnancy losses |
Q90415557 | Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management |
Q57807704 | Chloroquine attenuates TLR3-mediated plasminogen activator inhibitor-1 expression in cultured human glomerular endothelial cells |
Q38994352 | Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: comparison with Euro-Phospholipid cohort |
Q42269209 | Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome |
Q37642830 | Current management of antiphospholipid syndrome-related thrombosis |
Q51252221 | Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. |
Q26771128 | Do neutrophil extracellular traps contribute to the heightened risk of thrombosis in inflammatory diseases? |
Q37721607 | Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome |
Q44220064 | Dyslipidaemia in patients with lupus nephritis. |
Q34161393 | Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort |
Q53190790 | Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. |
Q38745362 | Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis |
Q50737245 | Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study. |
Q38782057 | Emerging Therapies in Antiphospholipid Syndrome |
Q41914711 | Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus |
Q37399457 | Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy |
Q48459103 | Haralampos M. Moutsopoulos: A lifetime in autoimmunity |
Q38663014 | How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores |
Q64069038 | Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study |
Q47680027 | Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. |
Q58608546 | Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome |
Q33747286 | Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug |
Q34003992 | Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression |
Q41934841 | Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome |
Q37827403 | Hydroxychloroquine: from malaria to autoimmunity |
Q38856073 | IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis |
Q38883883 | Immunomodulators in SLE: Clinical evidence and immunologic actions |
Q38826804 | Immunotherapeutic strategies in antiphospholipid syndrome |
Q35711767 | Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosus |
Q40725518 | Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study |
Q51332462 | Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome. |
Q26774815 | Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives |
Q33730536 | Management of cardiovascular complications in systemic lupus erythematosus |
Q38180647 | Management of recurrent thrombosis in antiphospholipid syndrome |
Q64910478 | Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. |
Q90289969 | Multiple embolic strokes as a result of Libman-Sacks endocarditis associated with lupus and secondary antiphospholipid antibody syndrome: a case report |
Q39440991 | New Insights on Platelets and Platelet-Derived Microparticles in Systemic Lupus Erythematosus. |
Q38026787 | New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. |
Q34140319 | New therapeutic targets for the antiphospholipid syndrome |
Q55440072 | Nonbacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome. |
Q50052184 | Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. |
Q33574487 | Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations |
Q36966870 | Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus |
Q52349399 | Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview. |
Q39138695 | Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study |
Q38794847 | Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population? |
Q24633010 | Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
Q39027911 | Prevention of thrombosis in antiphospholipid syndrome |
Q37812011 | Primary Thrombosis Prophylaxis in Antiphospholipid Antibody–Positive Patients: Where Do We Stand? |
Q48274065 | Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. |
Q38392607 | Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review |
Q33692770 | Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety |
Q35925359 | Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. |
Q53113544 | Solid Phase Immunoassay for the Detection of Anticardiolipin Antibodies. |
Q88399624 | The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository |
Q37721612 | The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis |
Q38873953 | The antiphospholipid syndrome: from pathophysiology to treatment. |
Q38680580 | The association between ABO blood types and venous thromboembolism in individuals with a positive antiphospholipid profile is varied by sex. |
Q28072610 | The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus |
Q38257820 | The clinical utility of anti-ribosomal P autoantibodies in systemic lupus erythematosus |
Q38125246 | The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus |
Q94672281 | The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? |
Q37947108 | The role of antimalarial agents in the treatment of SLE and lupus nephritis |
Q33904653 | The role of neutrophils and NETosis in autoimmune and renal diseases |
Q36147794 | Thrombosis in systemic lupus erythematosus: a review article |
Q37642828 | Thrombosis in systemic lupus erythematosus: risk and protection |
Q38135335 | Top 10 clinical research developments in antiphospholipid syndrome |
Q38149851 | Transient ischemic attack and stroke in systemic lupus erythematosus |
Q38205079 | Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. |
Q35621012 | Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches |
Q37803363 | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients |
Q39027915 | What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies? |
Q90416101 | [Antiphospholipid syndrome : Update on diagnostics and management] |
Q87831212 | [Antiphospholipid syndrome] |
Q41375519 | β2-Glycoprotein I-Dependent Anti-Cardiolipin Antibodies Associated With Periodontitis in Patients With Systemic Lupus Erythematosus. |
Search more.